Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Buclin, Thierry ^a,b   Telenti, Amalio ^a   Perera, Rafael ^b   Csajka, Chantal ^a,c   Furrer, Hansjakob ^d   Aronson, Jeffrey K ^b   Glasziou, Paul P ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MONITORING; NONHUMAN; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; SWITZERLAND; SYSTEMATIC REVIEW; VIREMIA; VIRUS LOAD; ARTICLE; DECISION MAKING; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; NOMOGRAM; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DECISION MAKING; HEALTH PLANNING GUIDELINES; HIV INFECTIONS; HIV-1; HUMANS; NOMOGRAMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79954519438     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018578     Document Type: Review

References (48)

1. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA 304: 321-333.
2. Hammer SM, Clinical practice (2005) Management of newly diagnosed HIV infection. N Engl J Med 353: 1702-1710.
3. Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD, (2007) When should antiretroviral therapy for HIV be started? BMJ 334: 76-78.
4. Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, et al. (2008) Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med 148: 178-185.
5. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
6. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352-1363.
7. World Health Organization (2006) WHO HIV/AIDS Programme: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. Available: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed December 2010.
8. Severe P, Jean Juste MA, Ambroise A, Eliacin L, Marchand C, et al. (2010) Early versus standard antiretroviral therapy for HIVinfected adults in Haiti. N Engl J Med 363: 257-265.
9. Kent DM, McGrath D, Ioannidis JPA, Bennish ML, (2003) Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis 37 (S1): S13-S24.
10. Kimmel AD, Losina E, Freedber KA, Goldie SJ, (2006) Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries. Bull World Health Organ 84: 581-588.
11. Hallett TB, Gregson S, Dube S, Garnett GP, (2008) The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modelling. PLoS Med 5: e53.
12. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, et al. (2008) Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a Southern African analysis. Arch Intern Med 168: 1910-1918.
13. Egger M, (2008) Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 13: 870-879.
14. Smit C, Hallett TB, Lange J, Garnett G, de Wolf F, (2008) Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS ONE 3: e1949.
15. Glasziou PP, Irwig L, Aronson JK, (2008) Evidence-based Medical Monitoring: From Principles to Practice Oxford Blackwell Publishing BMJ books.
16. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
17. Stevens RJ, Oke J, Perera R, (2010) Statistical models for the control phase of clinical monitoring. Stat Methods Med Res 19: 394-414.
18. Sheiner LB, Beal S, Rosenberg B, Marathe VV, (1979) Forecasting individual pharmacokinetics. Clin Pharmacol Ther 26: 294-305.
19. Touloumi G, Hatzakis A, Rosenberg PS, O'Brien TR, Goedert JJ, (1998) Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia. Multicenter Hemophilia Cohort Study. AIDS 12: 1691-1697.
20. DeGruttola V, Lange N, Dafni U, (1991) Modeling the progression of HIV infection. J Amer Stat Assoc 86: 569-577.
21. Faucett CL, Thomas DC, (1996) Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach. Stat Med 15: 1663-1685.
22. Lepri AC, Sabin CA, Pezzotti P, England PD, Phillips AN, et al. (1997) Is there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion Study. J Infect Dis 175: 775-780.
23. Lange N, Carlin BP, Gelfand AE, (1992) Hierarchical Bayes models for the progression of HIV infection using longitudinal CD4 T-cell numbers. J Amer Stat Assoc 87: 615-626.
24. Laurent C, Bourgeois A, Faye MA, Mougnutou R, Seydi M, et al. (2002) No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study. J Infect Dis 186: 486-492.
25. CASCADE Collaboration (2003) Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 34: 76-83.
26. Taffé P, May M, (2008) A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat Med 27: 4835-4853.
27. Phillips AN, Sabin C, Pillay D, Lundgren JD, (2007) HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med 8: 536-546.
28. Hoover DR, Graham NM, Chen B, Taylor JM, Phair J, et al. (1992) Effect of CD4+ cell count measurement variability on staging HIV-1 infection. J Acquir Immune Defic Syndr 5: 794-802.
29. Raboud JM, Montaner JS, Conway B, Haley L, Sherlock C, et al. (1996) Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 174: 191-194.
30. McNeil AJ, (1997) Bayes estimates for immunological progression rates in HIV disease. Stat Med 16: 2555-2572.
31. Madec Y, Boufassa F, Porter K, Meyer L, (2005) Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 19: 2001-2007.
32. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
33. Phair JP, Mellors JW, Detels R, Margolick JB, Muñoz A, (2002) Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 16: 2455-2459.
34. Rodríguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, et al. (2006) Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296: 1498-1506.
35. Anastos K, Gange SJ, Lau B, Weiser B, Detels R, et al. (2000) Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 24: 218-226.
36. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action (2000) Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 355: 1131-1137.
37. Daar ES, Kesler KL, Wrin T, Petropoulo CJ, Bates M, et al. (2005) HIV-1 pol replication capacity predicts disease progression. AIDS 19: 871-877.
38. Piroth L, Binquet C, Buisson M, Kohli E, Duong M, et al. (2004) Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)? Eur J Epidemiol 19: 597-604.
39. Van der Paal L, Shafer LA, Mayanja BN, Whitworth JAG, Grosskurth H, (2007) Effect of pregnancy on HIV disease progression and survival among women in rural Uganda. Trop Med Int Health 12: 920-928.
40. Telenti A, Goldstein DB, (2006) Genomics meets HIV-1. Nat Rev Microbiol 4: 865-873.
41. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942-947.
42. Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, et al. (2007) Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA 297: 2349-2350.
43. Bakari M, Urassa W, Mhalu F, Biberfeld G, Pallangyo K, et al. (2008) Slow progression of HIV-1 infection in a cohort of antiretroviral naïve hotel workers in Dar es Salaam, Tanzania as defined by their CD4 cell slopes. Scand J Infect Dis 40: 407-413.
44. May M, Wood R, Myer L, Taffe P, Rauch A, et al. (2009) CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland. J Infect Dis 200: 1729-1735.
45. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, (2008) Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 148: 656-661.
46. Lomax N, Curtis H, Johnson M, (2009) A national review of assessment and monitoring of HIV-infected patients. HIV Med 10: 125-128.
47. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, et al. (2008) Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371: 1443-1451.
48. Boscardin WJ, Taylor JM, Law N, (1998) Longitudinal models for AIDS marker data. Stat Met Med Res 7: 13-27.